Can I contact factories directly on CNFX?

CNFX is an open directory. Each factory profile provides direct contact information.

Active Pharmaceutical Ingredient (API) Component – Chemical Manufacturing

Component Specifications

Definition

Active Pharmaceutical Ingredient (API) is the substance in a pharmaceutical drug that produces the intended pharmacological effect. In tablet manufacturing, APIs are combined with excipients through processes like granulation, blending, and compression to form the final dosage form. APIs must meet strict purity, potency, and stability standards as defined by pharmacopeias and regulatory agencies.

Working Principle

APIs work through specific biochemical interactions with biological targets (e.g., receptors, enzymes) to produce therapeutic effects. In tablet formulation, APIs are uniformly distributed within excipient matrices to ensure consistent dosage delivery upon ingestion and dissolution.

Materials

APIs are typically organic compounds (small molecules) or biologics (proteins, peptides) with defined chemical structures. Common materials include synthetic chemicals, plant extracts, or fermentation products. Specifications include chemical purity (>98-99.5%), particle size distribution (10-200 μm), polymorphism control, and moisture content (<0.5%).

Technical Parameters

Purity ≥98.5%
Potency 95-105% of labeled amount
Stability 24-month shelf life under specified conditions
Solubility Water-soluble or lipid-soluble as required
Bulk Density 0.4-0.8 g/cm³
Particle Size D90 < 150 μm

Standards

ISO 9001, ISO 13485, ICH Q7, USP, EP, JP

Industry Taxonomies & Aliases

Commonly used trade names and technical identifiers for Active Pharmaceutical Ingredient (API).

Parent Products

This component is used in the following industrial products

Pharmaceutical Tablets

A pharmaceutical tablet is a solid dosage form produced by compressing a mixture of active pharmaceutical ingredients and excipients into a uniform shape and size.

View Product Details

Engineering Analysis

Risks & Mitigation

Contamination with impurities
Polymorphism changes affecting bioavailability
Degradation during storage
Cross-contamination in manufacturing
Regulatory non-compliance

FMEA Triads

Trigger: Inadequate purification during synthesis
Failure: High impurity levels exceeding specifications
Mitigation: Implement multi-step purification processes and in-process controls

Trigger: Improper storage conditions
Failure: API degradation reducing potency
Mitigation: Maintain controlled temperature and humidity storage with monitoring

Trigger: Particle size variation
Failure: Inconsistent tablet content uniformity
Mitigation: Implement milling and sieving controls with regular particle size analysis

Industrial Ecosystem

Compatible With

Interchangeable Parts

Compliance & Inspection

Tolerance

±5% for assay, ±0.1% for related substances, ±10% for particle size distribution

Test Method

HPLC for purity, USP dissolution testing, Karl Fischer for moisture, laser diffraction for particle size, microbial enumeration per USP <61>

Procurement Evaluation Criteria

Not customer reviews or live demand data. These dimensions support RFQ preparation and supplier evaluation.

Technical documentation

4/5

Manufacturing capability

4/5

Inspection readiness

5/5

Supplier transparency

3/5

These scores are example evaluation dimensions, not real customer ratings, country-specific buyer feedback, or live inquiry activity.

Related Components

In-line Analyzer Port

In-line analyzer port for real-time chemical composition monitoring in continuous flow reactors

Seeding Port

A precision port for introducing seed crystals into batch crystallization systems to initiate controlled crystal growth.

Sight Glass

A transparent window for visual inspection of fluid flow and crystallization processes in industrial systems.

Control Software

Specialized software for real-time monitoring and control of continuous flow pharmaceutical reactors, ensuring precise process parameters and regulatory compliance.

Frequently Asked Questions

What is the difference between API and finished dosage form?

API is the pure drug substance that provides therapeutic effect, while finished dosage form (like tablets) contains API combined with excipients for administration.

How are APIs tested for quality?

APIs undergo rigorous testing including identity, assay, impurity profiling, residual solvents, microbial limits, and physical characterization per pharmacopeial standards.

What are common sources of APIs?

APIs are sourced from chemical synthesis, fermentation, extraction from natural sources, or recombinant DNA technology for biologics.

Can I contact factories directly?

Yes, each factory profile provides direct contact information.

Data Basis

CNFX manufacturer profiles, technical classification, publicly available product information, and ongoing plausibility checks.

Preliminary Technical Classification

This page supports structured research, RFQ preparation, and supplier evaluation. It does not replace buyer-led supplier qualification, standards review, or technical approval.

Active Pharmaceutical Ingredient (API)